The South Korean government has announced significant reforms to its national health insurance drug pricing system. The policy aims to improve patient access to innovative and essential medicines while reducing the financial burden of pharmaceuticals. These measures are also designed to stimulate innovation in the domestic pharmaceutical industry. The reforms were discussed and approved at the 6th Health Insurance Policy Deliberation Committee held on March 26, 2026.
The changes will impact patients, pharmaceutical companies, and healthcare providers. Notably, the reimbursement period for new drugs, including treatments for rare diseases, will be shortened from up to 240 days to within 100 days. Generic drug prices will be reduced from 53.55% to 45% of the original price, and special incentives will be provided to innovative and small-to-medium pharmaceutical companies. The policy also strengthens supply stability for essential medicines and introduces expanded support for specialized medical services, including alcohol treatment.
Implementation will begin in the second quarter of 2026, with phased adjustments over approximately ten years for existing drugs. The government will expand the scope of flexible price contracts to include more drug types and will enhance post-market performance evaluations. Essential medicines will receive price and supply incentives if domestic production and raw material self-sufficiency conditions are met. The reforms also introduce regular price adjustments and improved monitoring to ensure predictability and stability.
Frequently asked questions include: Who benefits from these reforms? Patients needing new or essential medicines, pharmaceutical companies, and healthcare providers will see improved access and incentives. What are the main changes for generic drugs? Their prices will be lowered, and excessive market entry will be controlled through stricter price steps and listing management. How will essential medicine supply be secured? The government will offer incentives for domestic production and designate leading supply companies for additional price benefits.
Metaqsol opinion: South Korea’s drug pricing reforms are a significant step toward improving healthcare access and affordability. The reduction in reimbursement times for new drugs and the cut in generic drug prices will directly benefit patients and encourage pharmaceutical innovation. By also focusing on supply stability and support for essential medicines, the policy addresses both current and future healthcare challenges. The phased approach and targeted incentives suggest a well-considered plan that balances industry and public health interests.